Title: On a Quest to Select the Right Site First Time, 2p.

Oriol Serra Ortiz, MS Global Product Development Mohanish Anand, PhD, MS (Pharm Med) Global Product Development, Pfizer, Inc. The global investigative site landscape has reached an inflection point. Mergers and acquisitions, and companies sharing and pooling data, are some of the strategies aimed to make site selection more effective, yet rumor has it that sponsors and CROs are not satisfied with site identification and site selection efforts. Can we challenge the status quo to truly develop a more efficient approach to select the right site the first time? At Pfizer we are on a quest to answer this question. As part of Pfizer’s overall strategy to put innovation in the forefront of our business practice across the planning and execution of our trials, Pfizer has invested in areas of Protocol Design Optimization, Strategic Feasibility, Enrollment Modelling and Patient Recruitment and Site intelligence and Selection to become a key part of our overall Study Optimization framework. Following this organizational effort in 2018, after almost two years of a cross functional effort that assessed the internal and external landscape, we created the Site Intelligence and Selection team within our Global Product Development organization to drive this paradigm shift.

Click Here For Complete Article Text

 

   Person Information
   Application Sequencing
 325412 - Pharmaceutical Preparation Manufacturing                
Company  Product  Process  Other  Subjects  Event  Event  Date  Location  Publication  Publication  Date Text  Descriptor

 

  • Location

 

 

 

  • Pharmaceutical Outsourcing

 

  • 7/1/2019

 

  • Article